Serina Therapeutics Inc
SER5.170USD
-0.120-2.27%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
51.35MMarket Cap
LossP/E TTM
More Details of Serina Therapeutics Inc Company
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Company Info
Ticker SymbolSER
Company nameSerina Therapeutics Inc
IPO dateNov 29, 2018
CEOMr. Steven Ledger
Number of employees12
Security typeOrdinary Share
Fiscal year-endNov 29
Address601 Genome Way,
CityHUNTSVILLE
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code35806
Phone12563279630
Websitehttps://serinatherapeutics.com/
Ticker SymbolSER
IPO dateNov 29, 2018
CEOMr. Steven Ledger
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Director
Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Director
Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 28
Updated: Wed, May 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Juvenescence Ltd
32.78%
Puffinus L.P.
9.08%
McMillan (Helen w)
8.45%
Fisk (Barbara M.)
5.38%
Loya (Miguel)
4.23%
Other
40.08%
Shareholders
Shareholders
Proportion
Juvenescence Ltd
32.78%
Puffinus L.P.
9.08%
McMillan (Helen w)
8.45%
Fisk (Barbara M.)
5.38%
Loya (Miguel)
4.23%
Other
40.08%
Shareholder Types
Shareholders
Proportion
Corporation
41.86%
Individual Investor
21.99%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
1.12%
Hedge Fund
1.10%
Research Firm
0.04%
Other
32.76%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
59
6.70M
67.24%
+259.47K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
2023Q2
62
604.05K
55.98%
-7.36K
2023Q1
65
604.47K
56.02%
-8.31K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Juvenescence Ltd
3.27M
32.78%
--
--
Mar 01, 2025
Puffinus L.P.
904.88K
9.08%
--
--
Mar 01, 2025
McMillan (Helen w)
842.40K
8.45%
+133.79K
+18.88%
Mar 01, 2025
Fisk (Barbara M.)
536.28K
5.38%
+33.81K
+6.73%
Mar 01, 2025
Loya (Miguel)
422.10K
4.23%
--
--
Mar 01, 2025
Ledger (Steven A)
323.66K
3.25%
+95.73K
+42.00%
Mar 28, 2025
Broadwood Capital, Inc.
85.22K
0.85%
--
--
Mar 31, 2025
Waverly Advisors, LLC
67.49K
0.68%
--
--
Mar 31, 2025
Bailey (Gregory Hugh)
67.24K
0.67%
--
--
Mar 01, 2025
The Vanguard Group, Inc.
65.33K
0.66%
+3.26K
+5.25%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Date
Type
Ratio
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
Mar 07, 2024
Merger
35.17<1
